FMR LLC reports 9.7% stake in Veracyte
Veracyte Inc. amendment to Schedule 13G/A reports that FMR LLC (and Abigail P. Johnson through related entities) beneficially owns 7,703,848.74 shares of common stock, representing 9.7% of the class.
Rhea-AI Filing Summary
Veracyte Inc. amendment to Schedule 13G/A reports that FMR LLC (and Abigail P. Johnson through related entities) beneficially owns 7,703,848.74 shares of common stock, representing 9.7% of the class. The filing lists sole dispositive power of 7,703,848.74 shares and discloses a related Exhibit 99 13d-1(k)(1) agreement.
Positive
- None.
Negative
- None.
Insights
Passive 13G amendment shows FMR LLC holds a 9.7% stake in Veracyte.
FMR LLC is reporting beneficial ownership of 7,703,848.74 shares and sole dispositive authority for the same amount. The amendment format and the use of Exhibit 99 indicate reporting under beneficial‑owner rules rather than an active acquisition described here.
For investors, this is a disclosure of significant shareholding; the filing does not state trading intent or plans. Subsequent filings would show material changes in the stake or voting intentions.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially owned financial
dispositive power regulatory
13d-1(k)(1) agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does FMR LLC report in VCYT?
Is this a Schedule 13G or 13D disclosure for VCYT?
Does the filing indicate any sale or purchase plans by FMR LLC?
What exhibits accompany the filing and what do they indicate?
AI-generated analysis. How Rhea-AI works. Not financial advice.